IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN MULTIPLE RECALL/REFRACTORY MYELOMA (MMRR): ANALYSIS OF HIGH-RISK PATIENT SUBGROUPS (PTS) FROM THE KARMMA STUDY

被引：0

作者：

Jesus, San-Miguel ^{[1
]}

Noopur, Raje S. ^{[2
]}

David, Siegel ^{[3
]}

Sundar, Jagannath ^{[4
]}

Sagar, Lonial ^{[5
]}

Nikhil, Munshi C. ^{[6
,7
]}

Philippe, Moreau ^{[8
]}

Hartmut, Goldschmidt ^{[9
,10
]}

Michele, Cavo ^{[11
]}

Anna, Truppel-Hartmann ^{[12
]}

Everton, Rowe ^{[13
]}

Huang Liping ^{[13
]}

Amit, Agarwal ^{[13
]}

Julie, Wang ^{[13
]}

Timothy, Campbell B. ^{[13
]}

Donna, Reece E. ^{[14
]}

机构：

[1] Clin Univ Navarra, Pamplona, Spain

[2] Hosp Gen Massachusetts, Boston, MA 02114 USA

[3] Ctr Med Univ Hackensack, Hackensack, NJ USA

[4] Mt Sinai Hosp, New York, NY 10029 USA

[5] Escuela Med Emory, Atlanta, GA USA

[6] Harvard Med Sch, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA

[7] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

[8] Ctr Hosp Univ Nantes, Nantes, France

[9] Hosp Univ Heidelberg, Heidelberg, Germany

[10] Natl Ctr Tumor Dis, Heidelberg, Germany

[11] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[12] Bluebird Bio, Cambridge, MA USA

[13] Bristol Myers Squibb, Princeton, NJ USA

[14] Ctr Oncol Princess Margaret, Toronto, ON, Canada

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CO-069

引用

页码：77 / 77

页数：1

共 50 条

[21] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED KARMMA RESULTS
Cavo, M.
Oriol, A.
San-Miguel, J.
Kansagra, A.
Madduri, D.
Shah, N.
Moreau, P.
Yakoub-Agha, I.
Delforge, M.
Einsele, H.
Goldschmidt, H.
Weisel, K.
Rambaldi, A.
Reece, D.
Rodriguez-Otero, P.
Petrocca, F.
Connarn, J.
Patel, P.
Huang, L.
Campbell, T.
Hege, K.
Munshi, N.
HAEMATOLOGICA, 2021, 106 (10) : 5 - 5
[22] KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.
Usmani, Saad Z.
Berdeja, Jesus G.
Truppel-Hartmann, Anna
Fei, Yizhou
Wortman-Vayn, Honeylet
Shelat, Suresh
Novick, Steven
Shah, Nina
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[23] Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial
Ayers, Dieter
Cope, Shannon
Dhanda, Devender S.
Towle, Kevin
Mojebi, Ali
Delforge, Michel
Rodriguez-Otero, Paula
Trudel, Suzanne
Weisel, Katja
Zamagni, Elena
Hari, Parameswaran
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S139 - S140
[24] Idecabtagene Vicleucel (ide-cel, bb2121), A BCMA-Directed Car T cell therapy, in patients with Relapsed and Refractory Multiple Myeloma (RRMM): Initial KarMMa results
Einsele, H.
Weisel, K.
Goldschmidt, H.
Munshi, N. C.
Anderson, L. D., Jr.
Shah, N.
Jagannath, S.
Berdeja, J.
Lonial, S.
Raje, N.
Siegel, D. S.
Lin, Y.
Oriol, A.
Moreau, P.
Yakoub-Agha, I
Delforge, M.
Petrocca, F.
Connarn, J. N.
Patel, P.
Huang, L.
Campbell, T. B.
Hege, K.
San Miguel, J.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 90 - 91
[25] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-Cell therapy, in patients with relapsed and refractory multiple myeloma: Updated KarMMa results
Einsele, H.
Oriol, A.
San-Miguel, J.
Kansagra, A.
Madduri, D.
Shah, N.
Moreau, P.
Yakoub-Agha, I
Delforge, M.
Cavo, M.
Goldschmidt, H.
Weisel, K.
Rambaldi, A.
Reece, D.
Rodriguez-Otero, P.
Petrocca, F.
Connarn, J. N.
Patel, P.
Huang, L.
Campbell, T. B.
Hege, K.
Munshi, N. C.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 120 - 121
[26] Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs)
Mashadi-Hossein, Afshin
Rytlewski, Julie
Shamsuzzaman, Md
Basudhar, Debashree
Takhar, Mandeep
Kostic, Ana
Campbell, Timothy Brandon
Manier, Salomon
Lin, Yi
Martin, Nathan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[27] ESTIMATION OF POST-INFUSION COSTS OF CARE FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVED IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN THE KARMMA CLINICAL TRIAL
Hari, P.
Nguyen, A.
Pelletier, C.
Hege, K.
McGarvey, N.
Gitlin, M.
Parikh, K.
VALUE IN HEALTH, 2021, 24 : S29 - S30
[28] Idecabtagene vicleucel (ide-cel; bb2121); a BCMA-directed CAR T cell therapy; for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
Einsele, Hermann
Anderson, Larry D., Jr.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus
Lonial, Sagar
Raje, Noopur
Siegel, David S.
Lin, Yi
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Goldschmidt, Hartmut
Weisel, Katja
Cavo, Michele
Reece, Donna
Rambaldi, Alessandro
Truppel-Hartmann, Anna
Patel, Payal
Huang, Liping
Campbell, Timothy B.
Hege, Kristen
San-Miguel, Jesus
Munshi, Nikhil C.
Oriol, Albert
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 173 - 173
[29] Quality of life in patients (pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with the BCMA-DIRECTED CAR T cell therapy Idecabtagene Vicleucel (IDE-CEL, bb2121): Results from the KarMMa trial
Weisel, K.
Einsele, H.
Goldschmidt, H.
Delforge, M.
San Miguel, J.
Bertin, K. B.
Tahir, M.
Lewis, H.
Wang, J.
Braverman, J.
Campbell, T. B.
Munshi, N.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 93 - 94
[30] Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma
Thompson, Ethan G.
Jiang, Yue
Campbell, Timothy B.
Fuller, Jaymes
Kaiser, Shari
Mashadi-Hossein, Afshin
Rytlewski, Julie
Martin, Nathan
Finney, Olivia
Kleinsteuber, Katja
Alonzo, Eric
Pandya, Chetanya
Agarwal, Amit
Hege, Kristen
Raje, Noopur S.
Munshi, Nikhil C.
Hause, Ronald J.
BLOOD, 2019, 134

← 1 2 3 4 5 →